Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor Conferences

Rhea-AI Summary

Eiger BioPharmaceuticals, focused on targeted therapies for rare diseases, announced participation in two investor conferences in August 2020. Management will engage in a fireside chat at the BTIG Virtual Biotechnology Conference on August 10, from 12:30-12:55 PM ET, and present a corporate update at the Wedbush PacGrow Virtual Healthcare Conference on August 12, from 3:30-4:00 PM ET. Both events will feature live webcasts on Eiger's website. Eiger is advancing treatments for Hepatitis Delta Virus and has pending applications for lonafarnib, with an FDA PDUFA date set for November 20, 2020.

PALO ALTO, Calif., Aug. 3, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor conferences in August.

• BTIG Virtual Biotechnology Conference 2020. Eiger will participate in a fireside chat with live webcast on Monday, August 10, 12:30-12:55 PM ET. Eiger will also host one-on-one meetings.

• 2020 Wedbush PacGrow Virtual Healthcare Conference. Eiger will present a corporate update with live webcast on Wednesday, August 12, 3:30-4:00 PM ET. Eiger will also host one-on-one meetings.

Live webcasts of the BTIG fireside chat and Wedbush presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab. A replay of the webcast will be available approximately one hour following the live event.

About Eiger
Eiger is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs, for which no approved therapies exist. 

Eiger's lead programs target Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis. Eiger is developing two complementary treatments for HDV. Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial. Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.

Eiger has filed an NDA and MAA for lonafarnib for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies. FDA PDUFA date is November 20, 2020.  

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors and Media:
Ingrid Choong, PhD
(650) 619-6115
ichoong@eigerbio.com

Sri Ryali
(650) 272-6138
sryali@eigerbio.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2020-investor-conferences-301104509.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

When is Eiger BioPharmaceuticals participating in the BTIG Virtual Biotechnology Conference?

Eiger BioPharmaceuticals will participate in the BTIG Virtual Biotechnology Conference on August 10, 2020, from 12:30-12:55 PM ET.

What is the date of Eiger's presentation at the Wedbush PacGrow Virtual Healthcare Conference?

Eiger will present a corporate update at the Wedbush PacGrow Virtual Healthcare Conference on August 12, 2020, from 3:30-4:00 PM ET.

How can I watch the live webcasts for Eiger's conference presentations?

Live webcasts of both the BTIG and Wedbush presentations will be available on Eiger's website under the 'Investors' tab.

What is the FDA PDUFA date for Eiger's lonafarnib application?

The FDA PDUFA date for Eiger's lonafarnib application is November 20, 2020.

What are Eiger BioPharmaceuticals' main focus areas?

Eiger BioPharmaceuticals focuses on developing treatments for serious rare and ultra-rare diseases, particularly targeting Hepatitis Delta Virus.